Screener
Cyclerion Therapeutics
CYCNCyclerion Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for serious neuropsychiatric disorders.
$19.43M+136%
Earnings
Next report
Nov 11, 2026 (in 2 months)Revenue estimate$900.0K
EPS estimate-$6.00
Competitors
Profile
Cyclerion Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for serious neuropsychiatric disorders. The company leverages its expertise in soluble guanylate cyclase (sGC) pharmacology to create a pipeline of novel therapeutics aimed at conditions with high unmet medical needs.
Competitive position
A specialized clinical-stage player focusing on novel sGC stimulators for central nervous system disorders.
GeographiesUnited States
Customer segmentsPatients, Medical professionals
Business modelR&D intensive, Biotechnology drug development
SuppliersContract research organizations, Raw material suppliers, Scientific research institutions
CustomersHospitals, Specialty pharmacies, Clinical trial participants
CountryUnited States of America
Listed2019
Employees1.0
CEORegina Graul
SectorHealthcare
IndustryBiotechnology
Websitecyclerion.com
FilingsSEC EDGAR
FAQ
- What is Cyclerion Therapeutics's market cap?
- Cyclerion Therapeutics (CYCN) has a market capitalization of $19.4M and trades on NASDAQ.
- Who are Cyclerion Therapeutics's competitors?
- Cyclerion Therapeutics's key competitors include Johnson & Johnson, Minerva Neurosciences, Inc, LB Pharmaceuticals Inc Common Stock, and others. These companies compete in similar markets and product categories.
- Where is Cyclerion Therapeutics headquartered?
- Cyclerion Therapeutics is headquartered in United States of America and employs approximately 1 people. It has been publicly traded since 2019.